Similarly, positive results have been announced regarding the phase II study with Lu AG09222 in migraine prevention (HOPE trial), with a statistically significantly greater reduction in the number of monthly migraine days (MMDs) from baseline to weeks 1 to 4 of treatment in patients treated with the antibody anti-PACAP ligand compared to placebo in the absence of tolerability issues. Here, ADCYAP1 is linked to migraine disorder.